|
[1]HONG Y,LONG J,LI H,et al.An analysis of immunoreactive signatures in early stage hepatocellular carcinoma[J].EBioM edicine,2015,2(5):438-446.
|
|
[2]POON D,ANDERSON BO,CHEN LT,et al.Management of hepatocellular carcinoma in Asia:consensus statement from the Asian Oncology Summit 2009[J].Lancet Oncol,2009,10(11):1111-1118.
|
|
[3]MASUZAKI R,KARP SJ,OMATA M.New serum markers of hepatocellular carcinoma[J].Semin Oncol,2012,39(4):434-439.
|
|
[4] CAVIGLIA GP,ABATE ML,PETRINI E,et al.Highly sensitive alpha-fetoprotein,Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection[J].Hepatol Res,2016,46(3):e130-e135.
|
|
[5] DAI M,CHEN X,LIU X,et al.Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma:a Meta-analysis[J].PLoS One,2015,10(10):e0140067.
|
|
[6]WANG L,YAO M,PAN LH,et al.Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma[J].Hepatobiliary Pancreat Dis Int,2015,14(4):361-366.
|
|
[7]EL-DIN BESSA SS,ELWAN NM,SULIMAN GA,et al.Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma[J].Arch Med Res,2010,41(7):541-547.
|
|
[8]GAO WF,ZHENG JS,SUN B.The clinical value of AFP in the diagnosis of hepatocellular carcinom[J].Curr Physician,2010,16(32):19-20.(in Chinese)高文峰,郑加生,孙斌.甲胎蛋白在原发性肝癌诊断中的临床价值[J].当代医学,2010,16(32):19-20.
|
|
[9]FARINATI F,MARINO D,DE GIORGIO M,et al.Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma:both or neither?[J].Am J Gastroenterol,2006,101(3):524-532.
|
|
[10]ERTLE JM,HEIDER D,WICHERT M,et al.A combination of alpha-fetoprotein and des-gamma-carboxy prothrombin is superior in detection of hepatocellular carcinoma[J].Digestion,2013,87(2):121-131.
|
|
[11]TAN EM,ZHANG J.Autoantibodies to tumor-associated antigens:reporters from the immune system[J].Immunol Rev,2008,222:328-340.
|
|
[12]CASIANO CA,MEDIAVILLA-VARELA M,TAN EM.Tumor-associated antigen arrays for the serological diagnosis of cancer[J].Mol Cell Proteomics,2006,5(10):1745-1759.
|
|
[13]TAN HT,LOW J,LIM SG,et al.Serum autoantibodies as biomarkers for early cancer detection[J].FEBS J,2009,276(23):6880-6904.
|
|
[14] MADRID FF,MAROUN MC,OLIVERO OA,et al.Autoantibodies in breast cancer sera are not epiphenomena and may participate in carcinogenesis[J].BMC Cancer,2015,15:407.
|
|
[15]UMMANNI R,DUSCHARLA D,BARETT C,et al.Prostate cancer-associated autoantibodies in serum against tumor-associated antigens as potential new biomarkers[J].J Proteomics,2015,119:218-229.
|
|
[16]HONG Y,HUANG J.Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma[J].World J Hepatol,2015,7(11):1581-1585.
|
|
[17]GADELHAK NA,GADELHAK SA,EL-MORSI DA,et al.Prognostic significance of three hepatitis markers(p53 antibodies,vascular endothelial growth factors and alpha fetoprotein)in patients with hepatocellular carcinoma[J].Hepatogastroenterology,2009,56(94-95):1417-1424.
|
|
[18] WANG Z,GOU W,LIU M,et al.Expression of P53 and HSP70 in chronic hepatitis,liver cirrhosis,and early and advanced hepatocellular carcinoma tissues and their diagnostic value in hepatocellular carcinoma:an immunohistochemical study[J].Med Sci Monit,2015,21:3209-3215.
|
|
[19] HM EI-E,GADELHAK SA,ABDELAZIZ MM,et al.Serum P53Abs in HCC patients with viral hepatitis-type C[J].Hepatogastroenterology,2014,61(134):1688-1695.
|
|
[20]LOOI K,MEGLIORINO R,SHI FD,et al.Humoral immune response to p16,a cyclin-dependent kinase inhibitor in human malignancies[J].Oncol Rep,2006,16(5):1105-1110.
|
|
[21]YUN JP,MIAO J,CHEN GG,et al.Increased expression of nucleophosmin/B23 in hepatocellular carcinoma and correlation with clinicopathological parameters[J].Br J Cancer,2007,96(3):477-484.
|
|
[22]LIU M,VARELA-RAMIREZ A,LI J,et al.Humoral autoimmune response to nucleophosmin in the immunodiagnosis of hepatocellular carcinoma[J].Oncol Rep,2015,33(5):2245-2252.
|
|
[23]GOC A,ABDALLA M,AL-AZAYZIH A,et al.Rac1 activation driven by 14-3-3zeta dimerization promotes prostate cancer cellmatrix interactions,motility and transendothelial migration[J].PLoS One,2012,7(7):e40594.
|
|
[24]CHOI JE,HUR W,JUNG CK,et al.Silencing of 14-3-3zeta over-expression in hepatocellular carcinoma inhibits tumor growth and enhances chemosensitivity to cis-diammined dichloridoplatium[J].Cancer Lett,2011,303(2):99-107.
|
|
[25]NEAL CL,YAO J,YANG W,et al.14-3-3zeta overexpression defines high risk for breast cancer recurrence and promotes cancer cell survival[J].Cancer Res,2009,69(8):3425-3432.
|
|
[26]LIU M,LIU X,REN P,et al.A cancer-related protein 14-3-3zeta is a potential tumor-associated antigen in immunodiagnosis of hepatocellular carcinoma[J].Tumour Biol,2014,35(5):4247-4256.
|
|
[27]WANG HG,WU QY,ZHOU H,et al.The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians:a meta-analysis[J].Asian Pac J Cancer Prev,2014,15(13):5277-5281.
|
|
[28]YOSHIDA A,USHIKU T,MOTOI T,et al.MDM2 and CDK4 immunohistochemical coexpression in high-grade osteosarcoma:correlation with a dedifferentiated subtype[J].Am J Surg Pathol,2012,36(3):423-431.
|
|
[29]HASHEMI M,OMRANI M,ESKANDARI-NASAB E,et al.A40-bp insertion/deletion polymorphism of Murine Double Minute2(MDM2)increased the risk of breast cancer in Zahedan,Southeast Iran[J].Iran Biomed J,2014,18(4):245-249.
|
|
[30]QIU M,LIU Y,YU X,et al.Interaction between p53 codon 72and MDM2 309T>G polymorphisms and the risk of hepatocellular carcinoma[J].Tumour Biol,2016,37(3):3863-3870.
|
|
[31]LIU M,ZHENG SJ,CHEN Y,et al.Autoantibody response to murine double minute 2 protein in immunodiagnosis of hepatocellular carcinoma[J].J Immunol Res,2014,2014(1):906532.
|
|
[32]DAI L,REN P,LIU M,et al.Using immunomic approach to enhance tumor-associated autoantibody detection in diagnosis of hepatocellular carcinoma[J].Clin Immunol,2014,152(1-2):127-139.
|
|
[33]JIA X,GAO Y,ZHAI D,et al.Survivin is not a promising serological maker for the diagnosis of hepatocellular carcinoma[J].Oncol Lett,2015,9(5):2347-2352.
|
|
[34]EZZELDIN M,BORREGO-DIAZ E,TAHA M,et al.RalA signaling pathway as a therapeutic target in hepatocellular carcinoma(HCC)[J].Mol Oncol,2014,8(5):1043-1053.
|
|
[35]WANG K,CHEN Y,LIU S,et al.Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma[J].Int J Immunopathol Pharmacol,2009,22(3):735-743.
|
|
[36]CHEN Y,ZHOU Y,QIU S,et al.Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma[J].Cancer Lett,2010,289(1):32-39.
|
|
[37]HUANG G,ZHOU Z,WANG H,et al.CAPER-alpha alternative splicing regulates the expression of vascular endothelial growth factor(1)(6)(5)in Ewing sarcoma cells[J].Cancer,2012,118(8):2106-2116.
|
|
[38]BELL JL,WACHTER K,MUHLECK B,et al.Insulin-like growth factor 2 mRNA-binding proteins(IGF2BPs):post-transcriptional drivers of cancer progression?[J].Cell Mol Life Sci,2013,70(15):2657-2675.
|
|
[39]ZHANG JY,CHAN EK,PENG XX,et al.A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma[J].J Exp Med,1999,189(7):1101-1110.
|
|
[40]GUTSCHNER T,HAMMERLE M,PAZAITIS N,et al.Insulin-like growth factor 2 mRNA-binding protein 1(IGF2BP1)is an important protumorigenic factor in hepatocellular carcinoma[J].Hepatology,2014,59(5):1900-1911.
|
|
[41]ZHANG JY,MEGLIORINO R,PENG XX,et al.Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma[J].J Hepatol,2007,46(1):107-114.
|
|
[42]MIDDLETON CH,IRVING W,ROBERTSON JF,et al.Serum autoantibody measurement for the detection of hepatocellular carcinoma[J].PLoS One,2014,9(8):e103867.
|
|
[43]ZHANG JY,TAN EM.Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors[J].Expert Rev Mol Diagn,2010,10(3):321-328.
|
DownLoad: